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People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). 
This review outlines policy recommendations made in the 2014 World Health Organisation 
(WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. 
It also canvasses issues that will affect translation of these global guidelines into practice. 
The first global HCV guidelines released by WHO have recently advocated targeted HCV 
testing for PWID, assessment of liver disease and support for alcohol reduction during care. 
They also strongly advocate treatment using currently licenced direct-acting antiviral agents 
for all individuals, in particular PWID as a key affected population. New HCV treatment 
regimens have the potential to cure more than 90% of treated individuals. Scaling-up 
treatment among PWID has the potential to improve individual and population health by 
reducing HCV transmission, improving quality of life and supporting behaviour 
modifications that lead to less risk-taking over time.  
 
PWID face several barriers to accessing HCV care and treatment that need to be overcome. 
Testing services need re-orientation toward PWID, individuals need to be informed of their 
results and provided with direct linkage to ongoing care. Health services need to provide care 
in the community using simpler, cheaper and more accessible modes of delivery. Healthcare 
costs and pharmaceutical costs need to be minimised so PWID, who are highly marginalised, 
can access HCV treatment. Sustained scale-up of treatment for PWID could simultaneously 
improve individual health and achieve the goal of eliminating HCV transmission among this 
high-risk and vulnerable group. 
 
.   
   





Chronic hepatitis C virus (HCV) infection is a significant global health problem, affecting 
approximately 185 million individuals globally, many of whom are unaware of their infection 
[1, 2]. Among people who inject drugs (PWID), HCV prevalence is estimated at 60-70%, 
although there is substantial variation in burden of disease regionally and nationally [3] 
(Figure 1). Most new HCV infections in high-income countries (HIC) occur among PWID, 
while in low- and middle-income countries (LMIC), injecting behaviour is still a key risk 
factor for transmission [3]. Whilst HCV treatment uptake remains low, PWID in particular 
lack access to care and treatment due to practical, systematic and perceived barriers. Arising 
from its framework for global action on HCV, the World Health Organization (WHO) 
produced the first global Guidelines for the Screening, Care and Treatment of Persons with 
Hepatitis C Infection in April 2014 [4]. Along with other professional guidelines and 
community action programmes, the WHO guidelines aim to improve access to care and 
treatment, especially among key affected populations like PWID. 
 
This article first outlines key recommendations from the WHO guidelines, how PWID were 
considered in their development, and the relevance of each recommendation to care and 
treatment for PWID. Second, it considers the impact of treatment of PWID beyond the 
individual medical benefits to broader public health and social benefits. It then examines the 
translation of guidelines into practice exploring the current barriers to care and treatment, 
including finding cases, health service orientation, cost, and perceptions about behaviour 
modification and reinfection in the era of simpler treatment. Finally, this article identifies 
features that will enable treatment scale-up for PWID, including health infrastructure, 
community engagement and affordable care. It demonstrates that the confluence of new, 
simpler and highly-effective HCV antiviral agents overcome many of the perceived barriers 
for treating PWID; coupled with policy recommendations that promote equitable access  to 
medical care for PWID, there is hope that we can now dramatically decrease the burden of 
HCV infection among injecting populations worldwide.  
 
Global policy and guidelines 
The WHO Guidelines of 2014 are the first global HCV treatment guidelines issued by WHO. 
They are primarily targeted at policy-makers in LMIC formulating country-specific treatment 
programmes. Unlike clinical management guidelines issued by professional associations 
[e.g., 5], they use a public-health approach that aims to evaluate scientific evidence and make 
recommendations mindful of feasibility of implementation in resource-limited settings. These 
   




guidelines are informed by the results of several systematic reviews directed at key questions 
in HCV testing, care and treatment. They employ a standardised method to grade strength of 
evidence and make recommendations, taking into account benefits and harms, values and 
preferences, and resources [6]. These factors are evaluated by a guidelines development 
group comprising clinicians, researchers, programme managers, and community 
representatives (including people living with HCV and PWID), among other stakeholders. 
The key recommendations and levels of evidence developed from this process are 
summarised in Table 1.  
  
Recommendations on HCV screening and diagnosis 
The WHO Guidelines first address how best to identify people with chronic HCV infection; a 
systematic review examined interventions that promoted HCV testing of asymptomatic 
individuals [7]. This review investigated the effectiveness of targeted testing interventions on 
HCV case detection, treatment uptake, and prevention of liver-related morbidity. Studies 
evaluating targeted interventions – those directed at groups at higher risk of HCV, chiefly 
including PWID – were compared with no target intervention or routine practice. Targeted 
testing, compared to no targeted testing, was associated with increased cases detected 
[number of studies (n)=14; pooled relative risk (RR) 1.7, 95% CI 1.3-2.2] and patients 
commencing therapy (n=4; RR 3.3, 95% CI 1.1-10.0). Testing interventions delivered by 
practitioners increased test uptake and cases detected (n=12; RR 3.5, 95% CI 2.5-4.8; and 
n=10; RR 2.2, 95% CI 1.4-3.5, respectively), whereas more general media/information-based 
interventions were less effective (n=4; RR 1.5, 95 % CI 0.7-3.0; and n=4; RR 1.3, 95 % CI 
1.0-1.6, respectively). As a result, the WHO guidelines strongly recommend focusing HCV 
testing efforts on individuals in populations with a high HCV prevalence, which includes 
PWID in most contexts. Careful consideration of resources, testing modalities and local 
epidemiology would influence implementation of this recommendation.  
 
Since most laboratory testing or point-of-care diagnosis involved HCV antibody detection 
initially, a question arises as to when chronic HCV should be confirmed using nucleic acid 
testing (NAT) to detect HCV ribonucleic acid (RNA). HCV RNA testing immediately after 
antibody diagnosis provides individuals with their current infection status which might affect 
health-seeking or risk-taking behaviour [8, 9], as well as lead to linkage to care and treatment. 
In many contexts, particularly resource-poor settings, NAT testing is largely deferred until an 
individual is being considered for treatment which may be many years after diagnosis. No 
direct evidence was available to answer this question. Yet given the potential for PWID and 
   




others to reduce risk-taking behaviour or seek care with awareness of their HCV infection 
status, the WHO guidelines suggest that NAT testing be performed directly following a 
positive HCV antibody test, in addition to any HCV RNA testing as part of the assessment 
for receiving treatment for HCV. 
 
Recommendations on HCV care  
Models of HCV care, health resources and infrastructure vary widely. Moreover, HCV 
treatment is frequently delayed or is unavailable – particularly in LMIC – during which time 
liver disease may progress or behaviours might influence health status. Given the potential 
for alcohol to accelerate HCV-associated liver disease [10], screening and counselling for 
alcohol use and fibrosis assessment were considered two key elements of HCV care requiring 
comment in the WHO Guidelines. A systematic review was conducted to determine whether 
alcohol reduction interventions among people with HCV, compared with no intervention, 
were associated with reduced alcohol intake, changes in fibrosis or liver-related morbidity or 
mortality [11]. Five small, heterogeneous trials or cohort studies were identified that provided 
limited evidence that alcohol reduction interventions might be associated with a modest 
reduction in alcohol consumption among HCV-infected individuals with moderate-to-high 
alcohol intake [11]. An earlier meta-analysis of brief alcohol reduction interventions among 
people without HCV infection, compared with no intervention, found a similar, small 
reduction in total alcohol consumption from 313g/week to 275g/week; a 38g (3 standard 
drinks) mean reduction [12]. Accordingly, the WHO guidelines recommend that alcohol 
intake assessments be performed for all persons with HCV infection followed by the offer of 
a behavioural alcohol reduction intervention for persons with moderate-to-high alcohol 
intake. The WHO Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) 
package is one standardised tool designed for use in primary care, validated internationally, 
and can be helpful in screening PWID for co-morbid substance use and enable early 
intervention [13]. 
 
Fibrosis stage is frequently used to determine urgency of HCV treatment. Assessment of 
fibrosis for those with chronic HCV is largely dependent upon access to testing resources and 
trained staff. After reviewing the evidence for non-invasive, low-resource fibrosis 
assessment, the WHO Guidelines suggest that in resource-limited settings, the 
aminotransferase/platelet ratio index (APRI) or Fibrosis-4 score (FIB4) be used for the 
assessment of hepatic fibrosis rather than other non-invasive tests that require more resources 
such as elastography or Fibrotest. If it was available and resources allow, transient 
   




elastography was also recommended. A series of systematic reviews were conducted to 
assess the diagnostic yield of more complex and expensive tests (eg elastography) and simple 
biochemically and haematologically-derived indices (eg APRI and FIB4) [14]. They are 
summarised in a health technology assessment supporting the use of the APRI score (or 
FIB4) with high and low cut offs to determine the likelihood of cirrhosis or absence of 
significant fibrosis, respectively [14]. Easier, primary care assessment of fibrosis stage could 
help ensure that PWID with advanced liver damage are promptly referred for treatment. 
 
Recommendations on HCV treatment 
A series of systematic reviews were conducted of all approved HCV antiviral agents (at April 
2014), which included boceprevir, telaprevir, simeprevir and sofosbuvir using pegylated-
interferon (PEG-IFN) and ribavirin as the comparator. Given the need for guidance on 
treatment for LMIC settings, the effectiveness of pegylated-interferon was also appraised 
against standard interferon, which is still used in some contexts due to its lower cost.  
 
While new HCV agents have not been directly compared among PWID with non-PWID, an 
earlier meta-analysis that pooled responses in six studies using PEG-IFN and ribavirin among 
PWID demonstrated a sustained virological response (SVR) of 37% (95% CI 26-48%) among 
individuals with HCV-genotype-1 infection and 67% (95% CI 56%-78%) in genotypes-2 or -
3 infection [15]. These real-world virological responses among PWID are comparable to non-
injecting populations, supporting recommendations for HCV treatment among PWID. Given 
high-quality evidence for the benefits of HCV treatment on virological response, liver 
morbidity and mortality [4], the WHO stongly recommend that all adults and children with 
chronic HCV infection, including PWID, should be assessed for antiviral treatment. 
Moreover, a strong statement was made recommending PEG-IFN and ribavirin over standard 
interferon and ribavirin to discourage the use of standard interferon in LMIC.  
 
The additional effectiveness of the HCV protease inhibitors boceprevir, telaprevir and 
simeprevir added to PEG-IFN and ribavirin has been described elsewhere [16, 17]. In light of 
simpler, safer direct-acting antiviral therapies (DAAs), WHO conditionally recommended the 
addition of boceprevir or telaprevir with PEG-IFN and ribavirin. However, it strongly 
recommended simeprevir, PEG-IFN and ribavirin over PEG-IFN and ribavirin alone. A key 
consideration when using these regimens among PWID will be drug-drug interactions, which 
need individualising depending on co-morbidities such as HIV, substance use, and opioid 
substitution therapy (OST). Evidence for the use of sofosbuvir with PEG-IFN and ribavirin, 
   




and sofosbuvir with ribavirin alone, indicated SVR greater than 90% can be achieved with 
few significant side effects in clinical trial settings [18-20]. While these registration studies 
did not make a direct comparison of sofosbuvir regimens with PEG-IFN and ribavirin, the 
WHO guidelines strongly recommend sofosbuvir with or without PEG-IFN depending on 
genotype based on the evidence for high efficacy and low toxicity.  
 
Since the WHO Guidelines were published, further drug combinations have been licenced by 
the US Food and Drug Administration. Fixed-dose sofosbuvir and ledipasvir was licenced in 
October 2014 and is active against all genotypes (except with less genotype-3a activity, in 
particular), with >90% SVR when used for 12 weeks [18-20]. This combination tablet has the 
potential to reduce treatment complexity and improve treatment uptake dramatically [21]. 
Different oral combinations by other manufacturers have also completed phase-three 
evaluation and will soon follow or have followed through regulatory approval into clinical 
practice [22, 23]; their simplicity and low toxicity may be particularly helpful for overcoming 
barriers to treating PWID. 
 
Benefits of expanding HCV treatment to PWID 
The global policy environment promoted by WHO and scientific and community associations 
is now explicitly orientated toward expanding treatment access for PWID. The medical 
benefits for individuals with HCV infection and equity arguments are reflected strongly in 
such guidance. However, additional public health and social benefits also justify expanded 
treatment access, and might help allay residual reservations in some sectors about treatment 
of PWID.  
 
Public health benefits of treating PWID 
Despite the well-established effectiveness and low cost of current harm reduction strategies 
for PWID, including OST and needle-syringe programmes (NSP), these methods have been 
only partially effective at reducing HCV transmission, which is in part due to poor coverage 
[24]. Expanded treatment access, in addition to widely-implemented harm reduction 
strategies, could greatly reduce or eliminate ongoing HCV transmission. Mathematical 
modelling using Australian, British and Canadian data suggest that treating a relatively small 
proportion of PWID with chronic HCV infection could significantly reduce HCV prevalence 
over 15 years [25-29]. These models demonstrate that the impact on prevalence varies on the 
number of individuals treated, the background prevalence of HCV, treatment effectiveness, 
and the speed of treatment scale-up. HCV prevalence could halve if treatment with >90% 
   




SVR was scaled-up from the current rate of approximately 5 per 1000 PWID treated annually 
to 15, 40, or 76 per 1,000 PWID treated annually in Edinburgh (Scotland), Melbourne 
(Australia), and Vancouver (Canada), respectively (Figure 2) [28].  
 
Moreover, treating recent HCV infection may have a greater impact on transmission. The 
impact of injecting networks on HCV transmission are critical in understanding spread of 
disease, since individuals with more injecting partners have a greater incidence of infection 
and reinfection [30]. Based on social network models, treating an individual in conjunction 
with all their known partners could have the greatest prevention benefit and be practically 
implemented [31]. Two large clinical trials have been designed to examine this concept of 
HCV “treatment as prevention” and are currently underway among both community PWID 
and prison populations (see clinicaltrials.gov NCT02363517 and NCT02064049).  
 
Social benefits of treating PWID 
Chronic HCV infection adversely influences health-related quality of life (QOL) [32-34]. 
QOL changes in HCV may be related to cirrhosis or awareness of infection [33-35], since the 
natural history of HCV infection is to remain largely asymptomatic. Treatment with PEG-
IFN can impair QOL [32], while SVR has also been associated with improved QOL, albeit 
not in all studies [33, 36]. Since PWID are already a marginalised and vulnerable population, 
global access to interferon-free treatment would clearly be ideal for such individuals, may 
avoid treatment-related impairment of QOL, and could improve long-term QOL and enhance 
treatment uptake and utilisation of other health and support services.  
 
Diagnosing and linking PWID to care might also reduce needle-sharing out of concern for 
injecting partners. Two longitudinal cohort studies have evaluated the impact of HCV 
diagnosis on behaviour in the short term and over time [8, 9]; both found a reduction in 
frequency and prevalence of injecting drug use after diagnosis. While these benefits are 
small, such findings suggest that expanding access to care and treatment for PWID would 
increase diagnosis and lead to some positive behaviour change. Social functioning, which 
relates to stable accommodation, employment and inter-personal relationships, is often 
limited in PWID and is known to influence treatment uptake and side effects during HCV 
treatment [37-39]. Policies that promote simpler and less toxic therapies are less likely to 
affect social functioning during treatment.   
 
   




Translating policy into practice 
Despite the medical, public health and social benefits of HCV treatment for PWID, many 
practical, financial and knowledge barriers need to be overcome to translate global policy into 
practice.   
 
Testing and linkage to care 
Globally, low frequency of HCV testing among PWID is often a result of limited health-
seeking behaviours, lower uptake of preventative medical care and under-disclosure of 
injecting behaviour to clinicians due to real and perceived stigma [40, 41]. Confirmation of 
current HCV infection using NAT testing, given the additional healthcare episode, expense 
and follow-up of results also limits accurate diagnosis of chronic HCV. UNITAID have 
recently evaluated potential costs of diagnosis US$300-1400, excluding liver biopsy, and 
costs to patients can be highly variable [42]. Studies describing the HCV care cascade from 
diagnosis to treatment completion demonstrate attrition of individuals at every step in the 
care pathway [43]; this attrition is often exaggerated for PWID. Moreover, laboratory and 
public health surveillance systems largely lack the ability to determine new-onset HCV which 
reflects a period of high risk of onward HCV infection in PWID [44]. Innovate interventions 
that deliver testing, results and immediate pathways to care in the community, and 
surveillance systems that assist in identify recent infection could have substantial public 
health benefits for PWID.  
 
Health service organisation 
HCV care has traditionally been the provenance for specialists and tertiary care given the 
complexity of care, liver complications when treatment was initiated in advanced fibrosis, 
and funding models that favour clinician-led care. In order to offer HCV treatment to 
everyone living with infection, including PWID, an expansion in treatment services will be 
necessary. Task-shifting to primary care or other healthcare workers accompanied by 
appropriate workforce training and development will be critical given constraints on human 
resources and costs. It may also have the important benefit of accommodating patient 
preference, which might facilitate treatment uptake, adherence and quality of life. Peer 
workers will also be critical in designing models of care, providing education and support, 
and integrated into delivering care if treatment scale up is to be achieved and simplified. 
Several factors make a simplified model for HCV treatment delivery achievable: less 
individualised and more standardised pharmaceutical regimens; fewer side effects; less 
monitoring; and community HCV education. While the delivery of oral HCV therapies have 
   




not yet been evaluated outside of tertiary care settings, the safe use of PEG-IFN based 
treatment in prisons [45], primary care [46] and using nurse-led models of care [47] suggests 
new antivirals will be easier to deliver. Health services and programme managers have the 
opportunity – and challenge – to re-design their models of care to accommodate those with 
HCV and the needs of key populations like PWID.  
 
HCV treatment services frequently prioritise therapy for those with advanced liver disease 
given the risk of progression to liver failure and cancer, and resource limitations. However, 
current PWID compared to past PWID are, in general, more likely to have milder liver 
disease and so clinical guidelines [e.g. 5] that prioritise treatment for individuals with 
advanced fibrosis pose a potentially significant barrier to treatment for PWID [48]. Different 
public health outcomes could result from re-orientating HCV services at PWID versus those 
with advanced fibrosis. United Kingdom modelling indicated that prioritising treatment 
uptake among PWID will substantially impact on incident transmission; however, this 
approach foregoes the optimal impact on liver-related mortality. Conversely, targeting those 
with moderate or advanced fibrosis could have greater impact on liver mortality but may be 
suboptimal at averting incident infection [48]. The challenge for health systems will be 
whether they can orientate health services to offer therapy to individuals with both advanced 
fibrosis and PWID in the context of the current high drug prices.  
 
Affordable treatment  
Current policy to offer treatment to everyone will be impossible to implement without 
substantial falls in the cost of HCV antivirals. At the time of writing, treatment using 
sofosbuvir could cost as much as US$1000 per pill or US$84,000 for a 12 week course of 
treatment [49]. The current market price of medicines is likely to fall in some jurisdictions 
with generic manufacturing through voluntary licensing and competition from soon-to-be-
approved medications. Tiered pricing arrangements – where a manufacturer varies price by 
country and income status – are also likely to expand treatment access slightly by lowering 
prices at the country level. Nevertheless, individual PWID may still face unacceptably high 
barriers to treatment if out-of-pocket costs for medicines, laboratory tests and health care 
visits are not minimised or subsided locally. Short of compulsory licensing to grant generic 
manufactures authority to produce patented drugs, in the immediate future, cooperation 
between the pharmaceutical industry, governments and advocacy from healthcare providers 
and scientific and affected communities will be necessary to make treatment affordable for 
PWID.  
   





Ongoing innovation could further assist in price reductions. Potent pan-genotypic antiviral 
agents will further simplify treatment, avoid the need for expensive genotyping prior to 
therapy, and probably reduce the frequency of NAT testing during therapy. The licensing of 
fixed-dose combination therapy of sofosbuvir and ledipasvir for 12 weeks, with high SVR, 
with activity against most genotypes, and few side-effects makes treatment simplification 
realistic [18-20]. Newer regimens and research into treatment of acute HCV – which is 
particularly relevant to PWID given their risk of new infection – might also reduce the length 
of therapy further, and therefore lower cost substantially.  
 
The cost-effectiveness of chronic HCV treatment among PWID compared to former-PWID 
and non-injectors has been evaluated in some HIC settings. Modelling based on Australian 
healthcare costs and utility estimates derived from internationally has explored whether 
treatment of current PWID and former injectors, compared with those who have never 
injected, is cost-effective [50]. This research found that despite comorbidities, increased 
mortality from substance use, and reduced adherence, PEG-IFN and ribavirin treatment of 
both current and former PWID is cost-effective at under US$8,000 per quality-adjusted-life-
year gained, compared with under US$4,000 per quality-adjusted-life-year (QALY) gained in 
non-injectors. The model is highly sensitive to drug costs; the cost of first-generation protease 
inhibitors made some scenarios of early treatment not cost-effective. United Kingdom 
derived modelling among PWID prior to interferon-free therapy has come to similar cost-
effective conclusions [51]. However, if treatment of PWID were to have a significant 
prevention benefit and avert new cases of HCV infection, treatment could even be cost-
saving by averting future health costs. Despite the benefits and even if the new treatment 
regimens are “cost-effective”, assuming no immediate changes in drug prices, the financial 
challenge posed by medication and delivery costs for all people needing treatment would 
overwhelm current health systems.  
 
In this context, treatment aimed at people at risk of transmitting infection – including PWID – 
could become especially important since preventing new infections may make both public 
health and economic sense. A recent abstract evaluating scale-up of HCV treatment in the 
UK assessed the cost effectiveness of IFN-free DAAs delivered immediately compared with 
deferral until cirrhosis. The model assumed both individual and population prevention 
benefits of successful treatment. It found the greatest net monetary benefit and lowest cost 
per QALY among PWID with mild (GB£4650) or moderate (GB£2855) liver disease, while 
   




treatment of non-PWID cost GB£13,100-22,900 for each additional QALY. This analysis 
indicates that treatment of PWID – especially in low prevalence settings – averts HCV 
infections hence it becomes cost-effective to treat PWID early rather than delay treatment 
[52]. 
 
Perceptions about risk behaviours and treatment access 
HCV reinfection rates after chronic HCV treatment among PWID are generally low, 
estimated by one meta-analysis of five studies at 2.4 (95% CI, 0.9–6.1) per 100 person-years 
[15]. Nevertheless, concerns that risk-taking behaviour will increase as fear of disease and 
treatment declines in the era of highly-effective therapy – so called “risk compensation” – 
still persist and need addressing. The arguments mounted against treatment of PWID are 
three-fold: first, that as treatment becomes easier, individuals will be less concerned about 
reinfection and re-treatment; second, that PWID are unlikely to adhere to prolonged, self-
administered, oral therapy given perceived social instability; and third, that PWID accessing 
DAA treatment may no longer see HCV treatment as a key moment to make broader changes 
to their lifestyle.  
 
Insights from human immunodeficiency virus (HIV) infection – another chronic viral 
infection where highly active antiviral therapy has been available for nearly two decades – 
suggest that any correlation between risk-taking behaviour and treatment commencement is 
often overstated. In a meta-analysis of 60 studies, injecting risk-taking (measured by sharing 
needles/syringes) and sexual risk-taking (measured by inconsistent condom use and new 
sexually transmitted infection diagnoses) were not associated with commencement of HIV 
antiretroviral therapy [53]. Moreover, among those individuals on therapy, sexual risk-taking 
was marginally lower, reflecting that individuals commencing long-term therapy are probably 
self-selecting and lower risk-takers than those not undertaking therapy. Engagement with 
healthcare, support services and counselling coupled with treatment may have some role in 
reinforcing positive behaviour. Extrapolating from our knowledge of HIV, it is plausible that 
HCV therapy will not adversely influence risk-taking behaviour. Future research among 
PWID cohorts starting novel therapy should explicitly aim to measure changes in behaviour 
associated with treatment to assess whether simpler treatment has this theoretical impact.  
 
Treatment scale-up for PWID is also an opportunity to reinforce other established harm 
reduction measures, including increasing coverage of opiate substitution therapy [54, 55], 
needle and syringe programs [54, 56, 57], and frequent repeat HCV testing and counselling, 
   




particularly where cheap, reliable and rapid testing is available [58]. Expanded access to 
treatment should not come at a cost to these services; moreover it could facilitate their 
delivery and better integrate a range of HCV services.  
 
Conclusions 
Despite being a highly marginalised population, PWID can be engaged in care and treatment 
programmes, achieve comparable response to treatment in real-world settings, and have so far 
demonstrated low rates of reinfection long-term. The reasons for PWID traditionally being 
excluded from treatment can be largely overcome through treatment advances, advocacy and 
changes in policy. Moreover, there is an exciting prospect that treatment of PWID may confer 
both individual benefits and substantial population prevention benefits. To achieve this, 
national and international policy must facilitate the rapid scale-up of treatment and include 
PWID specifically in treatment access campaigns. Policies must also adapt rapidly to 
evolving research and effectively engage PWID in order to plan and deliver treatment 
services. It is conceivable that long-term goals could be set to eliminate HCV from within 
PWID in countries where testing and treatment programmes are widely available and 
accessible. The hope is that with widespread, efficacious treatment targeted at PWID, 
prevalent HCV will decline and HCV transmission will be effectively prevented.  
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Figure 1: Burden of HCV among PWID 
Estimated global population with history of HCV infection, chronic HCV infection, and 
PWID with chronic HCV infection. The estimated number of PWID globally is 16 million 
(range 11-21 million). PWID living with chronic HCV estimates (10 million, range 6-15 
million) compares to 2.8 million (range 1-6 million) PWID living with HIV infection [1, 3].  
 
 
Figure 2: DAA treatment scale up among PWID  
Chronic prevalence over time in (A) Edinburgh, (B) Melbourne, and (C) Vancouver. 
Simulations show no treatment scale-up from baseline, or scale-up to 10, 20, 40, or 80 per 
1,000 PWID treated annually assuming no treatment prior to 2002, a linear scale-up to 
baseline treatment rates during 2002-2007, and baseline treatment rates during 2007-2012. A 
linear scale-up from baseline to scaled-up rate during 2015-2017 was modelled.  
Reproduced from Martin et al, Hepatology, 2013 under Creative Commons Attribution 
License; copyright with authors [28].  
   






Table 1: WHO recommendations for the screening, care and treatment of persons with 
HCV infection (April 2014)[4] 
Recommendations on screening for HCV infection 
Screening to identify 
persons with HCV 
infection  
It is recommended that HCV serology testing be offered to individuals, 
who are part of a population with high HCV prevalence or who have a 
history of HCV risk exposure/behaviour.  
(Strong recommendation, moderate quality of evidence) 
When to confirm 
diagnosis of chronic 
HCV infection 
It is suggested that nucleic acid testing (NAT) for HCV ribonucleic acid 
(RNA) be performed directly following a positive HCV antibody test to 
establish the diagnosis of chronic HCV infection, in addition to HCV 
RNA testing as part of the assessment for receiving treatment for HCV. 
(Conditional recommendation, very low quality of evidence) 
Recommendations on care of people infected with HCV 
Screening for alcohol 
use and counselling to 
reduce moderate and 
high levels of alcohol 
intake 
An alcohol intake assessment is recommended for all persons with HCV 
infection followed by the offer of a behavioural alcohol reduction 
intervention for persons with moderate-to-high alcohol intake.  
(Strong recommendation, moderate quality of evidence)  
Assessing degree of 
liver fibrosis and 
cirrhosis 
In resource-limited settings, it is suggested that the 
aminotransferase/platelet ratio index (APRI) or FIB4 be used for the 
assessment of hepatic fibrosis rather than other non-invasive tests that 
require more resources such as elastography or Fibrotest.  
(Conditional recommendation, low quality of evidence) 
Recommendations on treatment of HCV infection 
Assessing for HCV 
treatment 
All adults and children with chronic HCV infection, including people 
who inject drugs, should be assessed for antiviral treatment.  




Pegylated interferon in combination with ribavirin is recommended for 
the treatment of chronic HCV infection rather than standard non-
pegylated interferon with ribavirin.  
(Strong recommendation, moderate quality of evidence) 
Treatment with 
telaprevir or boceprevir 
 
Treatment with direct-acting antivirals (telaprevir or boceprevir), given 
in combination with pegylated interferon and ribavirin, is suggested for 
genotype 1 chronic HCV infection rather than only pegylated interferon 
and ribavirin.  




Sofosbuvir, given in combination with ribavirin with or without 
pegylated interferon (depending on the HCV genotype), is recommended 
in genotypes 1, 2, 3 and 4 HCV infection rather than pegylated 
interferon and ribavirin alone (or no treatment for persons who cannot 




Simeprevir, given in combination with pegylated interferon and 
ribavirin, is recommended for persons with genotype 1b HCV infection 
and for persons with genotype 1a HCV infection without Q80K 
polymorphism rather than only pegylated interferon and ribavirin. This 
recommendation applies to persons with HCV monoinfection as well as 
those with HIV/HCV coinfection.  
(Strong recommendation, high quality of evidence) 
*These recommendations were made without taking resource use into consideration, as pricing 
information was not available for any country other than the United States at the time this 
recommendation was formulated. 
 
